Dr Prue Cowled
PhD
Principal Medical Scientist, RP Jepson Research Fellow, Affiliate Senior Lecturer
Contact details
Discipline of Surgery
Basil Hetzel Institute
The Queen Elizabeth Hospital
Ph: +61 8 8222 7541
Fax: +61 8 8222 7872
Email: prue.cowled@adelaide.edu.au
Biography
• 1992: Senior Visiting Scientist, European Molecular Biology Laboratory, Heidelberg, Germany
• 1994 - Present: Principal Medical Scientist, RP Jepson Research Fellow, Affiliate Senior Lecturer, Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital
• 1995 - Present: Post-graduate Coordinator, The University of Adelaide Discipline of Surgery, The Queen Elizabeth Hospital
Research interests
• Mechanisms of lower limb reperfusion injury: Role of the neutrophil.
• Nitric Oxide and reperfusion injury
• The small bowel as a target for remote damage after lower limb reperfusion injury
• Models for preoperative prediction of sepsis after open repair of abdominal aortic aneurysms
Recent publications
• Cowled PA, Khanna A, Laws PE, Field JB, Fitridge RA. Simvastatin plus nitric oxide synthase inhibition modulates remote organ damage following skeletal muscle ischemia-reperfusion injury. J Invest Surg 2008; 21(3):119-26.
Conferences
• Fifth International Conference, Biology, Chemistry and Therapeutic applications of Nitric Oxide, Austria, August 2008. Tissue nitrosothiol levels in acute ulcerative colitis - a step in disease induction. WEW Roediger and PA Cowled
• Detection, measurement and quantification of nitric oxide; Tools for NO Research. EUROSCICON, Biopark, Welwyn Garden City, UK. March 2007. Nitric Oxide inhibits cellular lipid and protein synthesis without energy depletion; a process of chronic disease due to nitrosothiols. WEW Roediger and PA Cowled
Students Supervised
Dr Achal Khanna - MPhil
Drew Grosser - BSc(Hons)
Grants
• TQEH Research Foundation Strategic Initiatives Funding Program Grant: JD Horowitz, J Beltrame, C Zeitz, DP Wilson, RJ Morris, B Sallustio, Y Chirkov, J Kennedy, PA Cowled, “Vascular Diseases and Therapeutics Research” 2009-2011 $540,000
|
